Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial

Obstet Gynecol Surv. 2025 Dec 1;80(12):757-759. doi: 10.1097/OGX.0000000000001475.

ABSTRACT

(Abstracted from Lancet Oncol 2025;26(10):1370-1381) Fifteen percent to 20% of endometrial cancer patients have a high-risk form of the disease; this classification indicates a higher risk of cancer recurrence and cancer-related death. The standard therapy for high-risk endometrial cancer is pelvic radiotherapy.

PMID:41468091 | DOI:10.1097/OGX.0000000000001475